Partners4Access, a leading market access consultancy specializing in orphan drugs, cell and gene therapy today announced its participation at the World Orphan Drug Congress, an industry conference that brings together rare disease stakeholders under a common platform.
The three-day event is being held between November 6-8, 2018 in Barcelona, Spain.
P4A’s Sophie Schmitz, Managing Partner and Christina Poschen, Consultant will be jointly presenting a segment of the conference on November 7 at 15:40 titled “The Secrets to Cell & Gene Therapy Success”.
The presentation will provide key insights, debunking the myths surrounding cell and gene therapy including industry segmentation on areas such as its curative and innovative features as well as long term impact and the expensive cost of therapy.
Using case studies, Sophie and Christina will illustrate the rapid evolution of the cell and gene therapy market focusing on sustainable value as one of the pivotal corner stones to achieve commercial success.
Sophie Schmitz said, “The enthusiasm and hype surrounding cell and gene therapies has not yet translated into widespread commercial success. Creating a sustainable business from these emerging therapies will be crucial to achieving commercial success. We will be sharing three of the secrets of gene therapy success at the WODC meeting in Barcelona.”
Exhibiting at stand #13, P4A’s Aparna Krishnan, Director – Operations and Communication and Nader Mourad, Senior Analyst will be joining Sophie and Christina to showcase the company’s expanding portfolio of services. These include, orphan drugs pricing and market access strategy; bespoke access roadmaps; rare disease foresights; evidence mitigation solutions and access team excellence.
The team will be available at the exhibition stand for additional inquiries and in-booth presentations throughout the event.
More details about the conference and its agenda are available at https://www.terrapinn.com/
P4A are specialists in access for orphan drugs, cell and gene therapy, partnering with the biotechnology industry to support launches worldwide. Focus areas include: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence. As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access.
Through its initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please email P4A at [email protected]